0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover276.35%IV-106.61%PremiumDec 20, 2024Expiry Date2.58Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7774Delta0.1879Gamma0.89Leverage Ratio-0.0109Theta-0.0020Rho-0.69Eff Leverage0.0017Vega
ADC Therapeutics Stock Discussion
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic respon...
NEWS
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
No comment yet